AstraZeneca vaccine found to be 79% effective in U.S. trial, ‘no increased risk’ of blood clots

Business

A healthcare professional draws up a dose of the Oxford/AstraZeneca Covid-19 vaccine at the vaccination centre set up inside Brighton Centre in Brighton, southern England, on January 26, 2021.
Ben Stensall | AFP | Getty Images

LONDON — The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% against severe disease and hospitalization.

The results were published Monday

It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people.

Germany, France, Italy and Spain are among those that have resumed use of the Oxford-AstraZeneca vaccine after Europe’s drug regulator said its initial investigation of possible side effects concluded the shot is safe and effective.

This is a developing story and will be updated shortly.

Articles You May Like

China’s economy reveals pockets of softness. Here’s what to watch ahead of Friday’s data
Siemens posts industrial profit drop as automation division slows
‘Wealth can be pretty isolating’: Problems that rich people face, according to therapists
529 college savings plans ‘are better now than they’ve ever been,’ expert says. Here are key changes for 2024
No ‘cop on the beat’: Why the SEC may deny new ether ETFs this month